Since going public in 2021 through a $1.6 billion SPAC deal, its grown into a major telehealth company, expanding into mental health and dermatology although Hims continues to post videos about, well: On May 20, Hims announced it would also sell its own version of GLP-1 weight loss injections like Ozempic and Wegovy
The medicine and its strength determine the price
Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, while Wegovy contains semaglutide, a high-dose GLP-1 receptor agonist specifically approved for chronic weight management
What Wont Address the Cause Biotin supplements unless a confirmed deficiency exists (which is rare), biotin wont help
Some researchers ask whether they can start higher